Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

J Mass Spectrom. 1998 Nov;33(11):1134-40. doi: 10.1002/(SICI)1096-9888(1998110)33:11<1134::AID-JMS730>3.0.CO;2-S.

Abstract

A method was developed for the bio-analysis of Ecteinascidin 743 (ET-743) using miniaturized liquid chromatography (LC) coupled to an electrospray ionization sample inlet (TurbolonSpray) and two quadrupole mass analyzers (LC/ESI-MS/MS). Solid-phase extraction was used as a sample pretreatment procedure. Ecteinascidin 743 is a very potent anticancer compound and is administered in microgram m-2 dosages, which demands special requirements in terms of sensitivity for the analytical method supporting clinical pharmacokinetic studies. Using conventional LC/UV, a lower limit of quantitation (LLQ) of 1 ng ml-1 plasma was reached using a 500 microliters sample volume, but LC/ESI-MS/MS permitted an LLQ of 10 pg ml-1. The latter method was found to be accurate and precise, and provided a broad linear concentration range of 0.010-2.50 ng ml-1.

Publication types

  • Clinical Trial

MeSH terms

  • Antineoplastic Agents / blood*
  • Antineoplastic Agents / pharmacokinetics
  • Chromatography, High Pressure Liquid
  • Dioxoles / blood*
  • Dioxoles / pharmacokinetics
  • Humans
  • Isoquinolines / blood*
  • Isoquinolines / pharmacokinetics
  • Mass Spectrometry
  • Reference Standards
  • Reproducibility of Results
  • Solutions
  • Tetrahydroisoquinolines
  • Trabectedin

Substances

  • Antineoplastic Agents
  • Dioxoles
  • Isoquinolines
  • Solutions
  • Tetrahydroisoquinolines
  • Trabectedin